GlaxoSmithKline (CAI:BIOC) Construction In Progress: E£123 Mil (As of Sep. 2016)


What is GlaxoSmithKline Construction In Progress?

GlaxoSmithKline CAI:BIOC +3.26% Construction In Progress is E£123 Mil as of Sep. 2016.

GlaxoSmithKline's quarterly construction in progress increased from Mar. 2016 (E£103 Mil) to Jun. 2016 (E£117 Mil) and increased from Jun. 2016 (E£117 Mil) to Sep. 2016 (E£123 Mil).

GlaxoSmithKline's annual construction in progress increased from Dec. 2013 (E£39 Mil) to Dec. 2014 (E£62 Mil) and increased from Dec. 2014 (E£62 Mil) to Dec. 2015 (E£78 Mil).

GlaxoSmithKline Construction In Progress Historical Data

* Premium members only.

The historical data trend for GlaxoSmithKline's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Construction In Progress Chart

GlaxoSmithKline Annual Data
Trend Dec12 Dec13 Dec14 Dec15
Construction In Progress
27.83 39.37 62.45 77.51

GlaxoSmithKline Quarterly Data
Dec12 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.82 77.51 102.64 116.53 123.20

GlaxoSmithKline Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of E£123 Mil mean?
GlaxoSmithKline (CAI:BIOC) has a Construction In Progress of E£123 Mil as of Sep. 2016. Construction in Progress records the amount of construction work that is not complete. View historical data on GlaxoSmithKline and its competitors.
Is GlaxoSmithKline's Construction In Progress too high?
GlaxoSmithKline's current Construction In Progress is E£123 Mil.
How does GlaxoSmithKline's Construction In Progress compare to PRPH?
GlaxoSmithKline's Construction In Progress of E£123 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on GlaxoSmithKline and its competitors. GlaxoSmithKline's current Construction In Progress is E£123 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline stock overvalued right now?
GlaxoSmithKline (CAI:BIOC) has a current Construction In Progress of E£123 Mil. The current Construction In Progress is E£123 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For GlaxoSmithKline (CAI:BIOC), the current Construction In Progress is E£123 Mil as of Sep. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GlaxoSmithKline Business Description

Address Boomerang Building, No 46, Block (J) First Section City Centre, Town Centre, Second floor, Fifth District - New Cairo, Cairo, EGY, 11835
GlaxoSmithKline is a pharmaceutical company. It is focused on developing new medicines in respiratory, HIV, oncology, and immune-inflation. The company is segmented into Commercial Operations and Total Research and development. It generates the majority of its revenue from the Commercial Operations segment.